![]() | ![]() |
Formats:
|
||||||||||||||||
Proteolytic cleavage of Chordin as a switch for the dual activities of Twisted gastrulation in BMP signaling Howard Hughes Medical Institute and Department of Biological Chemistry, University of California, Los Angeles, CA 90095-1662, USA *These authors contributed equally to this work ‡Author for correspondence (e-mail: derobert/at/hhmi.ucla.edu) The publisher's final edited version of this article is available free at Development. See other articles in PMC that cite the published article.SUMMARY Dorsoventral patterning is regulated by a system of interacting secreted proteins involving BMP, Chordin, Xolloid and Twisted gastrulation (Tsg). We have analyzed the molecular mechanism by which Tsg regulates BMP signaling. Overexpression of Tsg mRNA in Xenopus embryos has ventralizing effects similar to Xolloid, a metalloprotease that cleaves Chordin. In embryos dorsalized by LiCl treatment, microinjection of Xolloid or Tsg mRNA restores the formation of trunk-tail structures, indicating an increase in BMP signaling. Microinjection of Tsg mRNA leads to the degradation of endogenous Chordin fragments generated by Xolloid. The ventralizing activities of Tsg require an endogenous Xolloid-like activity, as they can be blocked by a dominant-negative Xolloid mutant. A BMP-receptor binding assay revealed that Tsg has two distinct and sequential activities on BMP signaling. First, Tsg makes Chordin a better BMP antagonist by forming a ternary complex that prevents binding of BMP to its cognate receptor. Second, after cleavage of Chordin by Xolloid, Tsg competes the residual anti-BMP activity of Chordin fragments and facilitates their degradation. This molecular pathway, in which Xolloid switches the activity of Tsg from a BMP antagonist to a pro-BMP signal once all endogenous full-length Chordin is degraded, may help explain how sharp borders between embryonic territories are generated. Keywords: TGFβ, BMP, Chordin, Tolloid, Twisted gastrulation, Crossveinless, Xenopus INTRODUCTION Dorsoventral patterning in developing embryos is established in part by a gradient of BMP (Bone Morphogenetic Protein) signaling. This gradient is generated in the extracellular space by the BMP antagonist Chordin (Chd), the zinc metalloproteinase Xolloid (Xld), and Twisted gastrulation (De Robertis and Sasai, 1996; Holley and Ferguson, 1997; De Robertis et al., 2000; Harland, 2001; Ray and Wharton, 2001). Chordin is a secreted protein containing four cysteine-rich domains (CRs) that mediate the direct binding of Chordin to BMP (Larraín et al., 2000). Binding of BMP to Chordin prevents binding of BMP to its cognate receptor (Piccolo et al., 1996), leading to dorsalization of Xenopus embryos in overexpression studies (Sasai et al., 1994; Sasai et al., 1995). In zebrafish, the strongest ventralized mutant, chordino, has been identified as a loss-of function mutation in the chordin gene (Schulte-Merker et al., 1997; Fisher and Halpern, 1999). In chordino mutants neural plate and dorsal mesoderm are reduced, and epidermis and ventral mesoderm are expanded at the gastrula stage (Hammerschmidt et al., 1996; Gonzalez et al., 2000). The opposite phenotype, dorsalization, is seen in bmp2b/swirl and bmp7/snailhouse loss-of-function mutants (Kishimoto et al., 1997; Schmid et al., 2000). In chordino:swirl double mutants, a swirl phenotype is seen, confirming that Chordin functions as a dedicated BMP antagonist (Hammerschmidt et al., 1996). In Drosophila, short gastrulation (sog) is the chordin homolog (François et al., 1994; Holley et al., 1995), and decapentaplegic (dpp) and screw (scw) encode BMP homologs (Holley and Ferguson, 1997; De Robertis et al., 2000). Loss of function of sog reveals two very different functions. In the ventral side, it is required for the formation of neural tissue (Zusman et al., 1988; François et al., 1994; Jaźwińska et al., 1999), as expected for a BMP antagonist. However, in the dorsal side, Sog is required for the formation of the amnioserosa, the dorsalmost tissue of the fly embryo, which requires maximal BMP signaling (Ferguson and Anderson, 1992; Ross et al., 2001). The latter effect is paradoxical, as it means that Sog, a BMP antagonist expressed in the ventral neuroectoderm, is required to attain peak BMP signaling at a distance. It has been proposed that Sog/BMP complexes originating from ventral regions diffuse in the embryo and that BMP is released dorsally by the proteolytic activity of Tolloid (Holley et al., 1996; Ashe and Levine, 1999; De Robertis et al., 2000; Harland, 2001). Tolloid (Tld) is a zinc metalloproteinase that plays a pivotal role in BMP metabolism in Drosophila (Ferguson and Anderson, 1992). Tld and its vertebrate homolog Xolloid (Xld) have been shown to cleave Sog/Chd at specific sites (Marqués et al., 1997; Piccolo et al., 1997; Goodman et al., 1998; Scott et al., 1999; Scott et al., 2001; Yu et al., 2000). Proteolytic cleavage of inactive Chordin/BMP complexes by Xolloid restores BMP signaling in Xenopus explants (Piccolo et al., 1997). The cleavage products of Chd contain functional CR modules that retain BMP binding activity (Larraín et al., 2000), raising the question of how the BMP signal is released and transferred to the receptor. Twisted gastrulation (Tsg) has been recently identified as an additional player in the Chd/Sog, BMP/Dpp, Xld/Tld signaling pathway (Oelgeschläger et al., 2000; Scott et al., 2001; Ross et al., 2001; Chang et al., 2001). Tsg encodes a secreted protein that is required for the differentiation of amnioserosa cells in Drosophila (Mason et al., 1994). It acts as a permissive factor specifically required for peak Dpp signaling in the dorsal midline (Mason et al., 1997; Ross et al., 2001). The isolation of a vertebrate homolog of Tsg revealed the presence of two evolutionarily conserved domains. The N-terminal domain has some sequence similarity to the CR domains of Chd/Sog and has been shown to bind directly to BMP (Oelgeschläger et al., 2000). Tsg has also been shown to bind to Chd and Sog (Oelgeschläger et al., 2000; Yu et al., 2000; Scott et al., 2001; Chang et al., 2001) and to facilitate the binding of Chd/Sog to BMP/Dpp (Oelgeschläger et al., 2000; Ross et al., 2001). Both pro- and anti-BMP activities have been described for Tsg in overexpression studies. In Xenopus, ubiquitous expression of Tsg mRNA leads to reduction of dorsal anterior markers at the early neurula stage (Oelgeschläger et al., 2000; Chang et al., 2001). However, in zebrafish, Tsg overexpression leads to dorsalization and in particular to a dramatic expansion of the expression domain of the hindbrain marker krox20 (Ross et al., 2001). In co-injection studies, Tsg is able to compete the residual anti-BMP activity of proteolytic fragments of Chordin generated by Xolloid, acting as a permissive pro-BMP factor (Oelgeschläger et al., 2000). However, in co-injections with full-length Chordin, two distinct effects of Tsg are seen. At low Tsg/Chd ratios, Tsg increases the dorsalizing activity of Chd, whereas at high concentrations Tsg inhibits Chordin (Ross et al., 2001; Chang et al., 2001; Oelgeschläger et al., 2000). As Tsg facilitates the binding of Chordin to BMP and the formation of a ternary complex, the matter of why Tsg would inhibit the activity of full-length Chordin at any concentration in vivo remains unresolved. We present studies on the mechanism of action of the various players in this biochemical pathway. We show that the inhibition of Chd activity by Tsg requires endogenous Xolloid activity and that microinjected Xenopus Tsg mRNA facilitates the degradation of endogenous Chordin protein in Xenopus embryos. Binding of Tsg to Chordin requires an intact C-terminal Xolloid cleavage site in Chd; once Chd is cleaved, Tsg/BMP complexes are released. Using binding to the BMP receptor as a biochemical assay, we show that Tsg has distinct and sequential activities on BMP metabolism. Initially, Tsg makes Chordin a better BMP antagonist by forming a ternary complex that prevents binding of BMP to its cognate receptor. After cleavage of Chordin by Xolloid, however, Tsg competes the residual inhibitory activity of Chordin fragments and promotes their degradation in vivo. We conclude that Xolloid acts as a proteolytic switch for the two functions of Tsg. The dual activities of Tsg, first antagonizing and then promoting BMP signaling, provides a novel molecular mechanism for the regulation of morphogenetic signals in the extracellular space. MATERIALS AND METHODS DNA constructs Xenopus Chd-A, Chd-B and Chd-C constructs were prepared using the Tolloid cleavage sites of mouse Chordin (Scott et al., 1999), which are conserved in the frog protein. For Chd-B the DNA between Asp147 and Ser853 was PCR amplified, and for Chd-C, the region from Asp854 to the C terminus was used. Chordin PCR products, as well as the mouse Tsg open reading frame, were introduced in frame into a pCS2 expression vector that contains the Xenopus Chordin signal peptide and the N terminus until Ala41, followed by a Flag tag sequence. The Chd-A construct has been described previously (pCS2-CR1) (Oelgeschläger et al., 2000). To generate Chd-A+B and Chd-B+C, BamHI and SphI internal sites were used, respectively. All constructs were linearized with NotI and transcribed with SP6 polymerase to generate synthetic mRNA using the mMessage mMachine kit (Ambion). Protein expression and purification Proteins used in Fig. 4
Protein biochemistry Assays for endogenous secreted Chordin were performed as described previously (Piccolo et al., 1996). In stage 10 dorsal lips incubated for 3 hours, only full-length secreted Chordin was detected. To visualize the cleavage products of endogenous Chordin, dorsal lips were explanted at stage 11 and the protein harvested after 12 hours of secretion at room temperature. In vitro digestions with the Xolloid protease were performed as described (Piccolo et al., 1997). For the BMP receptor (BMPR) binding assay, Chordin protein from baculovirus (Piccolo et al., 1996), affinity-purified Xenopus Tsg-HA and BMP4 (R&D Systems) were preincubated at room temperature for 1 hour. Then a BMPRIA-Fc protein (R&D Systems) was added for an additional hour. BMP bound to the BMPR was detected by anti-BMP4 western blot after protein A precipitation of the receptor (Larraín et al., 2000). Crosslinking and immunoprecipitation assays were performed as described (Larraín et al., 2000; Oelgeschläger et al., 2000). Antibody purification Antibodies for the N-terminal (anti-NChd) and for the inter-repeat (anti-I-Chd) region of Chordin were previously described (Piccolo et al., 1996; Piccolo et al., 1997). To analyze endogenous Chordin antisera were affinity-purified over nitrocellulose blots (Tang, 1993). Xenopus Chordin protein was separated by SDS-PAGE and transferred into nitrocellulose. Antibodies were bound to filter strips (for 16 hours at 4°C), washed five times (30 minutes each) with TBST, eluted on ice (for 3 minutes) with 2 ml of pH 2.8 buffer (0.1 M glycine, 0.5 M NaCl, 0.05% Tween-20) and immediately neutralized with 0.3 ml of 1 M Tris Buffer pH 8.0. For probing western blots, undiluted affinity-purified anti-NChd or a 1/3 dilution of anti-I-Chd were used. Embryo manipulations and RT-PCR Microinjections, in situ hybridization and mRNA synthesis were performed as described (Piccolo et al., 1997; Oelgeschläger et al., 2000; Sive et al., 2000). The probes for krox20 and otx2, gifts from Drs D. Wilkinson and E. Boncinelli, were linearized with EcoRI and NotI, respectively, and transcribed with T7 RNA polymerase (RT-PCR conditions and primers used are described at http://www.hhmi.ucla.edu/derobertis/index.html). For LiCl rescue experiments, embryos were microinjected ventrally at the 16-cell stage and treated with 120 mM LiCl in 0.1 × Barth’s medium (Sive et al., 2000) at the 32-64 cell stage for 25 minutes (Fainsod et al., 1994) and the dorsoanterior index (DAI) (Sive et al., 2000), estimated at stage 28. For lineage tracing of injected cells, 100 pg of lacZ mRNA was co-injected and visualized by Red-Gal staining. RESULTS Tsg and Xolloid ventralize Xenopus embryos In zebrafish, microinjection of Tsg mRNA leads to dorsalization of the embryo, in particular to an expansion of the hindbrain marker krox20 in the neural plate (Ross et al., 2001). By contrast, in Xenopus, Tsg mRNA microinjection causes reductions of anterior structures (Oelgeschläger et al., 2000; Chang et al., 2001). To investigate this further, the effects of mouse or Xenopus Tsg mRNA were compared with the phenotype caused by injection of Xolloid mRNA, a known pro-BMP agent (Piccolo et al., 1997; Goodman et al., 1998; Ferguson and Anderson, 1992). Tsg caused a reduction of the head region (marked by krox20 and otx2) similar to that caused by Xolloid (Fig. 1A-C
LiCl is a dorsalizing agent that causes a large increase in the expression of Chordin and other organizer-specific genes (Sasai et al., 1994; Wessely et al., 2001). We asked whether the increase of Chordin expression is essential for the LiCl phenotype, in which case Xolloid mRNA would be expected to rescue the dorsoanteriorized phenotype. Microinjection of Xolloid mRNA into a single blastomere of the marginal zone at the 16-cell stage partially rescued trunk-tail structures in LiCl treated embryos (Fig. 1E,F Tsg promotes the degradation of endogenous Chordin We next tested the effect of Tsg mRNA on endogenous Chordin protein in the Xenopus gastrula. Dorsal marginal zone explants (DMZ) were prepared at the early gastrula stage, cells dissociated in Ca2+/Mg2+ free saline, incubated for 3 hours, and the secreted Chordin protein analyzed by western blot. Two affinity-purified antibodies were used, one raised against the central region of Chordin and one specific for the N terminus (Fig. 2A
In Drosophila, Tsg changes the specificity of Tolloid cleavage causing the formation of a new fragment of the Chordin homolog Sog, called Supersog, which has been found both in embryo extracts and by in vitro digestion of Sog with Tolloid in the presence of Tsg (Yu et al., 2000). Supersog consists of the first CR repeat and additional amino acid sequence of the inter-repeat domain, and has novel inhibitory specificities (Yu et al., 2000). In Xenopus embryos, endogenous Chd proteolytic products could be detected in dissociated DMZ explants (Fig. 2E Ventralization by Xenopus Tsg requires Xolloid activity Embryos were microinjected with Tsg mRNA at the 32-cell stage into the animal pole and lineage traced with lacZ mRNA. As shown in Fig. 3A
The critical importance of Chordin proteolytic cleavage was also seen in experiments using a dominant-negative Tsg (dnTsg) construct consisting of only the C-terminal domain (Oelgeschläger et al., 2000). Injected dnTsg has opposing activities on full-length Xenopus Chordin or on the CR1 (Chd-A) fragment. When co-injected with Chordin, dnTsg mRNA inhibited the formation of double axes (Fig. 3L,M In zebrafish, overexpression of Tsg has a dorsalizing phenotype (Ross et al., 2001), which is the opposite of what we observe in Xenopus. Zebrafish embryos may have low levels of endogenous Tolloid activity, as the loss-of-function of Tolloid has only a weak mini-fin phenotype (Connors et al., 1999) and injection of dn Tld mRNA results in only mild dorsalization (Blader et al., 1997). A possible explanation for the difference in phenotypes (Fig. 3 Binding of Tsg to Chd is regulated by Xolloid The ventralizing activity of Tsg and its dependence on Xolloid activity suggests that the anti-BMP activity of ternary complexes should be inactivated by proteolytic cleavage of Chordin by Xolloid. To test this, we investigated the binding site of Xenopus Tsg in Chordin by subdividing the molecule into three fragments, designated Chd-A, Chd-B and Chd-C (Fig. 4A Chd-A, which contains the CR1 BMP-binding module does not form a ternary complex when incubated with Xenopus Tsg and BMP (Oelgeschläger et al., 2000). To determine whether Tsg is able to dislodge BMP pre-bound to Chd-A fragment, order-of-addition experiments were performed. After preincubation of Chd-A and BMP4 for 1 hour (Fig. 4D Taken together, the results suggest that formation of the ternary complex of full-length Chd, BMP and Xenopus Tsg requires an uncleaved C-terminal cleavage site. When Xolloid cleaves Chordin at this site, a binary complex of Tsg and BMP is released. Xolloid as a proteolytic switch To study the effects of Xenopus Tsg on BMP signaling, we used a direct assay measuring binding of BMP4 to a BMP-receptor-Fc fusion protein. In the presence of 0.5 or 5 nM full-length Chordin, 5 nM affinity-purified Xenopus Tsg protein potentiated the inhibition of receptor binding (Fig. 5A
When CR1 protein (Chd-A fragment, Fig. 4A The opposing activities of Tsg on full-length Chordin and on its proteolytic fragments suggested that the switch between the two activities of Tsg is controlled by the Xolloid metalloproteinase. This hypothesis was tested biochemically by digesting the inhibitory ternary complex with Xolloid and determining its effect on BMP binding to its receptor. We used conditions in which 0.5 nM BMP was quantitatively complexed with Chordin and Xenopus Tsg (5 nM each) for 1 hour. This blocked BMP binding to its receptor (Fig. 5C DISCUSSION We have examine the molecular mechanism by which Tsg regulates BMP signaling in the Xenopus embryo. Overexpression of vertebrate Tsg has a phenotypic effect comparable to that of Xolloid (Fig. 1 A model for BMP signaling regulation The opposing activities of Tsg on BMP binding to its receptor (Fig. 5
Multiple Chordin-like proteins A variety of extracellular proteins contain CR domains similar to those of Chordin. These include fibrillar procollagens (type I, II, III and V), members of the Nel-like family, CRIM-1, Kielin, Amnionless, Neuralin and Crossveinless 2 (Scriver et al., 1995; Watanabe et al., 1996; Kolle et al., 2000; Matsui et al., 2000; Kalantry et al., 2001; Coffinier et al., 2001; Conley et al., 2000). Several of these proteins, such as procollagen II, CRIM-1, Kielin, Neuralin and Crossveinless 2 (Cv-2), have been shown to modulate TGF-β/BMP signaling (Zhu et al., 1999; Larraín et al., 2000; Matsui et al., 2000; Coffinier et al., 2001; Nakayama et al., 2001; Conley et al., 2000). The case of Cv-2 is particularly interesting. This Drosophila molecule contains five adjacent CR domains of the Chordin type. cv-2 mutants lack the crossveins of the fly wing, which require peak Dpp signaling (Conley et al., 2000). A similar phenotype is observed in the wing after overexpression of Sog and in partial loss-of-function dpp alleles (Yu et al., 1996). Thus, Cv2 is a CR-containing protein that increases Dpp signaling. Another Drosophila mutation with the same defects in wing vein patterning is crossveinless (cv), first identified many years ago (Bridges, 1920). The mutation has been recently mapped to a second Drosophila Tsg gene homolog (L. Marsh, communication to Fly Base: FBgn0000394). Drosophila Tsg is required for peak BMP signaling in the dorsal midline of the fly embryo, and Cv is required for maximal BMP signaling in the crossveins of the wing. The observation that a second Tsg works together with the Cv-2 CR-containing protein in promoting BMP signaling suggests that the Chd/BMP/Xld/Tsg pathway shown in Fig. 6 Generating borders The present results provide mechanistic insights into how sharp borders may be generated in embryos. In Drosophila, Tsg is required for the peak BMP signaling (Mason et al., 1994; Mason et al., 1997) that induces a sharp band of Mad phosphorylation in the dorsal-most tissue (Ross et al., 2001). The pathway depicted in Fig. 6 Acknowledgments We thank Drs L. Zipursky, D. Schmucker and O. Wessely for comments on the manuscript, and S. Y. Li and A. Cuellar for technical assistance. M. O. and J. L. were HFSPO and Pew postdoctoral fellows, respectively. This work was supported by the NIH (R37 HD21502-15). E. M. D. R. is a Howard Hughes Medical Institute Investigator. REFERENCES
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||
Nature. 1996 Mar 7; 380(6569):37-40.
[Nature. 1996]Bioessays. 1997 Apr; 19(4):281-4.
[Bioessays. 1997]Nat Rev Genet. 2000 Dec; 1(3):171-81.
[Nat Rev Genet. 2000]Nature. 2001 Mar 22; 410(6827):423-4.
[Nature. 2001]Cell. 2001 Mar 23; 104(6):801-4.
[Cell. 2001]Development. 2000 Feb; 127(4):821-30.
[Development. 2000]Cell. 1996 Aug 23; 86(4):589-98.
[Cell. 1996]Cell. 1994 Dec 2; 79(5):779-90.
[Cell. 1994]Nature. 1995 Jul 27; 376(6538):333-6.
[Nature. 1995]Nature. 1997 Jun 26; 387(6636):862-3.
[Nature. 1997]Genes Dev. 1994 Nov 1; 8(21):2602-16.
[Genes Dev. 1994]Nature. 1995 Jul 20; 376(6537):249-53.
[Nature. 1995]Bioessays. 1997 Apr; 19(4):281-4.
[Bioessays. 1997]Nat Rev Genet. 2000 Dec; 1(3):171-81.
[Nat Rev Genet. 2000]Dev Biol. 1988 Oct; 129(2):417-27.
[Dev Biol. 1988]Development. 1992 Mar; 114(3):583-97.
[Development. 1992]Cell. 1997 Oct 31; 91(3):417-26.
[Cell. 1997]Cell. 1997 Oct 31; 91(3):407-16.
[Cell. 1997]Dev Biol. 1998 Mar 15; 195(2):144-57.
[Dev Biol. 1998]Dev Biol. 1999 Sep 15; 213(2):283-300.
[Dev Biol. 1999]Nature. 2000 Jun 15; 405(6788):757-63.
[Nature. 2000]Nature. 2001 Mar 22; 410(6827):475-8.
[Nature. 2001]Nature. 2001 Mar 22; 410(6827):479-83.
[Nature. 2001]Nature. 2001 Mar 22; 410(6827):483-7.
[Nature. 2001]Genes Dev. 1994 Jul 1; 8(13):1489-501.
[Genes Dev. 1994]Dev Biol. 1999 Sep 15; 213(2):283-300.
[Dev Biol. 1999]Nature. 2000 Jun 15; 405(6788):757-63.
[Nature. 2000]Cell. 1997 Oct 31; 91(3):407-16.
[Cell. 1997]Cell. 1996 Aug 23; 86(4):589-98.
[Cell. 1996]Cell. 1997 Oct 31; 91(3):407-16.
[Cell. 1997]Development. 2000 Feb; 127(4):821-30.
[Development. 2000]Nature. 2000 Jun 15; 405(6788):757-63.
[Nature. 2000]Cell. 1996 Aug 23; 86(4):589-98.
[Cell. 1996]Cell. 1997 Oct 31; 91(3):407-16.
[Cell. 1997]Methods Cell Biol. 1993; 37():95-104.
[Methods Cell Biol. 1993]Cell. 1997 Oct 31; 91(3):407-16.
[Cell. 1997]Nature. 2000 Jun 15; 405(6788):757-63.
[Nature. 2000]EMBO J. 1994 Nov 1; 13(21):5015-25.
[EMBO J. 1994]Nature. 2001 Mar 22; 410(6827):479-83.
[Nature. 2001]Nature. 2000 Jun 15; 405(6788):757-63.
[Nature. 2000]Nature. 2001 Mar 22; 410(6827):483-7.
[Nature. 2001]Cell. 1997 Oct 31; 91(3):407-16.
[Cell. 1997]Dev Biol. 1998 Mar 15; 195(2):144-57.
[Dev Biol. 1998]Cell. 1994 Dec 2; 79(5):779-90.
[Cell. 1994]Dev Biol. 2001 Jun 1; 234(1):161-73.
[Dev Biol. 2001]EMBO J. 1994 Nov 1; 13(21):5015-25.
[EMBO J. 1994]Nature. 2000 Jun 15; 405(6788):757-63.
[Nature. 2000]Nature. 2001 Mar 22; 410(6827):479-83.
[Nature. 2001]Nature. 2001 Mar 22; 410(6827):483-7.
[Nature. 2001]Development. 2000 May; 127(10):2143-54.
[Development. 2000]Cell. 1997 Oct 31; 91(3):407-16.
[Cell. 1997]Nature. 2001 Mar 22; 410(6827):475-8.
[Nature. 2001]Cell. 1997 Oct 31; 91(3):407-16.
[Cell. 1997]Nature. 2000 Jun 15; 405(6788):757-63.
[Nature. 2000]Nature. 2001 Mar 22; 410(6827):479-83.
[Nature. 2001]Development. 1999 Jun; 126(14):3119-30.
[Development. 1999]Science. 1997 Dec 12; 278(5345):1937-40.
[Science. 1997]Nature. 2000 Jun 15; 405(6788):757-63.
[Nature. 2000]Cell. 1997 Oct 31; 91(3):407-16.
[Cell. 1997]Dev Biol. 1999 Sep 15; 213(2):283-300.
[Dev Biol. 1999]Nature. 2001 Mar 22; 410(6827):475-8.
[Nature. 2001]Nature. 2000 Jun 15; 405(6788):757-63.
[Nature. 2000]Development. 2000 Feb; 127(4):821-30.
[Development. 2000]Nature. 2001 Mar 22; 410(6827):475-8.
[Nature. 2001]Nature. 2001 Mar 22; 410(6827):479-83.
[Nature. 2001]Nature. 2001 Mar 22; 410(6827):483-7.
[Nature. 2001]Nature. 2001 Mar 22; 410(6827):475-8.
[Nature. 2001]Nature. 2000 Jun 15; 405(6788):757-63.
[Nature. 2000]Nature. 2001 Mar 22; 410(6827):475-8.
[Nature. 2001]Nature. 2001 Mar 22; 410(6827):479-83.
[Nature. 2001]Nature. 2001 Mar 22; 410(6827):483-7.
[Nature. 2001]Development. 1997 Aug; 124(16):3177-84.
[Development. 1997]Genomics. 1996 Dec 15; 38(3):273-6.
[Genomics. 1996]Mech Dev. 2000 Feb; 90(2):181-93.
[Mech Dev. 2000]Proc Natl Acad Sci U S A. 2000 May 9; 97(10):5291-6.
[Proc Natl Acad Sci U S A. 2000]Nat Genet. 2001 Apr; 27(4):412-6.
[Nat Genet. 2001]Mech Dev. 2001 Jan; 100(1):119-22.
[Mech Dev. 2001]Development. 2000 Sep; 127(18):3947-59.
[Development. 2000]Development. 1996 Dec; 122(12):4033-44.
[Development. 1996]Proc Natl Acad Sci U S A. 1920 Nov; 6(11):660-3.
[Proc Natl Acad Sci U S A. 1920]Genes Dev. 1994 Jul 1; 8(13):1489-501.
[Genes Dev. 1994]Mech Dev. 1997 Jun; 64(1-2):61-75.
[Mech Dev. 1997]Nature. 2001 Mar 22; 410(6827):479-83.
[Nature. 2001]Nature. 2000 Jun 15; 405(6788):757-63.
[Nature. 2000]Cell. 1996 Aug 23; 86(4):607-17.
[Cell. 1996]